LONDON WALLET
  • Home
  • Investing
  • Business Finance
  • Markets
  • Industries
  • Opinion
  • UK
  • Real Estate
  • Crypto
No Result
View All Result
LONDON WALLET
  • Home
  • Investing
  • Business Finance
  • Markets
  • Industries
  • Opinion
  • UK
  • Real Estate
  • Crypto
No Result
View All Result
LondonWallet
No Result
View All Result

Sage Therapeutics’ stock craters 49% after FDA approves zuranolone for postpartum depression, but not major depressive disorder

Clyde Edgerton by Clyde Edgerton
August 7, 2023
in Markets
Sage Therapeutics’ stock craters 49% after FDA approves zuranolone for postpartum depression, but not major depressive disorder
74
SHARES
1.2k
VIEWS
Share on FacebookShare on Twitter


You might also like

Trump's approval holds steady despite unpopular policies, per new NYT poll

Trump is selling a strong economy. Voters aren’t buying it.

Former Trump statistics chief slams Friday firing of Erika McEntarfer

Sage Therapeutics Inc.’s stock
SAGE,
+0.25%
cratered 49% in premarket trade Monday, on disappointment that the U.S. regulator approved its zuranolone treatment for postpartum depression, but not for major depressive disorder, or MDD, which is a far broader condition. The Food and Drug Administration approved the treatment which was co-developed with Biogen Inc. in an announcement late Friday, making it the first-and-only oral treatment for post-partum, which affects one in eight new mothers in the U.S., according to CDC data. Until now, the only available option for this condition has been an intravenous injection that the FDA approved in 2019. It requires patients to stay in a hospital for two-and-a-half days. On Monday, Sage said its’s reviewing the feedback from the FDA and evaluating its next steps. “While we believe we are well capitalized, given the impact of the CRL (complete response letter) for zuranolone in MDD on our plans, we are currently evaluating resource allocation, including pipeline prioritization and a workforce reorganization with a goal of extending our cash runway,” CEO Barry Greene said in a statement. “With a right-sized organization and portfolio, we believe we have an opportunity to emerge as an even stronger company. We plan to provide greater detail and next steps before the end of the third quarter.” Biogen’s stock
BIIB,
+0.44%
was down 1.9% premarket.



Source link

Share30Tweet19
Previous Post

Worldcoin expects more companies to integrate in the coming months, says product head

Next Post

Making and shipping products as a side-hustle: What you need to know before you start

Clyde Edgerton

Clyde Edgerton

Recommended For You

Trump's approval holds steady despite unpopular policies, per new NYT poll
Markets

Trump's approval holds steady despite unpopular policies, per new NYT poll

September 30, 2025
Trump is selling a strong economy. Voters aren’t buying it.
Markets

Trump is selling a strong economy. Voters aren’t buying it.

September 13, 2025
Former Trump statistics chief slams Friday firing of Erika McEntarfer
Markets

Former Trump statistics chief slams Friday firing of Erika McEntarfer

August 3, 2025
Inside Trump’s chainsaw-wielding approach to one corner of government contracting
Markets

Inside Trump’s chainsaw-wielding approach to one corner of government contracting

May 25, 2025
Next Post
Making and shipping products as a side-hustle: What you need to know before you start

Making and shipping products as a side-hustle: What you need to know before you start

Related News

Invoice finance provider accelerated payments hits €1 billion funding milestone – London Business News | London Wallet

Invoice finance provider accelerated payments hits €1 billion funding milestone – London Business News | London Wallet

January 26, 2023
Casual gamers a ‘critical’ audience for blockchain games: GameFi execs

Casual gamers a ‘critical’ audience for blockchain games: GameFi execs

January 24, 2023
Letting agent handed 11-year ban – London Wallet

Letting agent handed 11-year ban – London Wallet

January 4, 2023

Browse by Category

  • Business Finance
  • Crypto
  • Industries
  • Investing
  • Markets
  • Opinion
  • Real Estate
  • UK

London Wallet

Read latest news about finance, business and investing

  • Contact
  • Privacy Policy
  • Terms & Conditions

© 2025 London Wallet - All Rights Reserved!

No Result
View All Result
  • Checkout
  • Contact
  • Home
  • Login/Register
  • My account
  • Privacy Policy
  • Terms and Conditions

© 2025 London Wallet - All Rights Reserved!

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?